EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults

Nick Miles, Brian McNamee, Cindy Zadikoff, Joey Boiser, Mohamad Shebley, Ramesh Boinpally

Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)

DOI: 10.1002/cpdd.70072 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.07.2026. Verfasst von Nick Miles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Membrane Glycoproteins, Nerve Tissue Proteins. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ABBV‐552, a positive modulator of synaptic vesicle glycoprotein 2A (SV2A), was under investigation as a treatment for cognitive impairment related to Alzheimer's disease. This Phase 1, multicenter, open‐label, parallel cohort study (NCT05686980) was conducted to examine the pharmacokinetics (PK), safety, and tolerability of ABBV‐552 in healthy adult Japanese and Han Chinese participants and to compare PK and safety findings with healthy adult Western participants from previous studies. Japanese participants in Cohort 1 (N = 10) received three ascending single oral doses (5, 15, and 40 mg) of ABBV‐552 with a washout of 7 days between doses. Han Chinese participants in Cohort 2 (N = 7) received a single oral dose of 40 mg ABBV‐552. After a single oral dose of 40 mg ABBV‐552, PK was comparable between both cohorts. Additionally, the range of individual ABBV‐552 concentrations and mean 24‐h profiles were comparable with historical data in healthy adult Western participants. In this small study population, single doses of ABBV‐552 were well tolerated at all tested doses. Common adverse events reported were dizziness (39%), somnolence (11%), and fatigue (11%). No unique safety signals following single dose ABBV‐552 administration were observed in the Japanese or Han Chinese populations examined compared with the previously examined Western population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMembrane GlycoproteinsNerve Tissue ProteinsAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralAsian PeopleDose-Response Relationship, DrugHealthy VolunteersWhite People

Stichwörter der Autor:innen

ABBV‐552ChineseJapaneseSV2Apharmacokinetics

Substanzen

Membrane GlycoproteinsNerve Tissue ProteinsSV2A protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.
  • Clinical Development Neuroscience, AbbVie Inc., North Chicago, IL, USA.
  • Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, IL, USA.

Förderung

  • AbbVie

Zitieren

APA

Miles, N., McNamee, B., Zadikoff, C., Boiser, J., Shebley, M., & Boinpally, R. (2026). Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70072

Vancouver

Miles N, McNamee B, Zadikoff C, Boiser J, Shebley M, Boinpally R. Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70072

BibTeX
@article{Miles2026,
  author = {Miles, Nick and McNamee, Brian and Zadikoff, Cindy and Boiser, Joey and Shebley, Mohamad and Boinpally, Ramesh},
  title = {Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cpdd.70072}
}
Kostenlos starten →